Quote | CYBIN INC. (AQNC:CYBN:CC)
Last: | $0.67 |
---|---|
Change Percent: | -1.47% |
Open: | $0.67 |
Close: | $0.67 |
High: | $0.68 |
Low: | $0.64 |
Volume: | 67,599 |
Last Trade Date Time: | 05/06/2022 04:52:03 pm |
News | CYBIN INC. (AQNC:CYBN:CC)
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting its audited financial results for the fiscal year en...
- Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (“BTD”) for CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder (“MDD”) - - Clinical si...
Message Board Posts | CYBIN INC. (AQNC:CYBN:CC)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
CYBIN INC. Company Name:
CYBN:CC Stock Symbol:
AQNC Market:
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting its audited financial results for the fiscal year en...
- Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (“BTD”) for CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder (“MDD”) - - Clinical si...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, will be spotlighted during an upcoming online fireside chat at the H.C. Wa...